HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Stern, Y. Articles by Cote, L. Search for Related Content PubMed PubMed Citation Articles by Stern, Y. Articles by Cote, L.

Pergolide therapy for Parkinson's disease

Neurobehavioral changes

From the Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY.

Article abstract-Pergolide mesylate, a long-acting dopamine agonist, is effective in treating Parkinson's disease. Behavioral change is said to be one adverse effect. We therefore studied 19 parkinsonian patients with neuropsychological tests before and after initiating pergolide therapy. Intellectual and behavioral changes were also monitored clinically for up to 2 years. There was no decline in performance on the neuropsychological tests. Six patients had transient psychiatric or intellectual changes that were controlled by reducing drug dosage. These changes were similar to those seen with other dopamine agonists.

Address correspondence and reprint requests to Dr. Stern, Neurological Institute, Box 15, 710 West 168th Street, New York, NY 10032.

This work was supported in part by the Parkinson's Disease Foundation (Dr. Stern) and by National Institutes of Health Award No. AG02802-01 (Dr. Mayeux).

Accepted for publication April 27, 1983.